Skip to main content
HCPCS Level II/M-Codes/M1191

M1191 HCPCS Level II Code: Hospice services provided to patient any time during the measurement period

Medicare Coverage & Payment

  • Medicare coverage: Carrier judgment (CMS coverage code C)
  • Payment category: Service not separately priced (pricing indicator 00)
  • BETOS: Z2 — Undefined codes
  • Last CMS action effective: January 1, 2023

Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.

Official Registry Overview & Definition

Hospice services provided to patient any time during the measurement period is a HCPCS Level II code (M1191). CMS assigns coverage code C — Carrier judgment. Short description: Hspc svc any time in meas pd.

Nearest Codes in This Family

Official HCPCS Level II classifications closest to M1191 in its code family, with their registry titles.

  • M1186 — Patients who have an order for or are receiving hospice or palliative care
  • M1187 — Patients with a diagnosis of end stage renal disease (esrd)
  • M1188 — Patients with a diagnosis of chronic kidney disease (ckd) stage 5
  • M1189 — Documentation of a kidney health evaluation defined by an estimated glomerular filtration rate (egfr) and urine albumin-creatinine ratio (uacr) performed
  • M1190 — Documentation of a kidney health evaluation was not performed or defined by an estimated glomerular filtration rate (egfr) and urine albumin-creatinine ratio (uacr)
  • M1192 — Patients with an existing diagnosis of squamous cell carcinoma of the esophagus
  • M1193 — Surgical pathology reports that contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both
  • M1194 — Documentation of medical reason(s) surgical pathology reports did not contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both tests were not included (e.g., patient will not be treated with checkpoint inhibitor therapy, no residual carcinoma is present in the sample [tissue exhausted or status post neoadjuvant treatment], insufficient tumor for testing)
  • M1195 — Surgical pathology reports that do not contain impression or conclusion of or recommendation for testing of mmr by immunohistochemistry, msi by dna-based testing status, or both, reason not given
  • M1196 — Initial (index visit) numeric rating scale (nrs), visual rating scale (vrs), or itchyquant assessment score of greater than or equal to 4